Glaxosmithkline | GSK - Ebit


Glaxosmithkline reported GBP2.15B in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Aurora Cannabis CAD -3.17M 10.29M Jun/2026
Bausch Health Companies USD 993M 217M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -2.03M 143.62M Jun/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Drreddys Laboratories INR 13.52B 10.47B Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 116.6M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Takeda JPY 205.32B 3.9B Sep/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026
Zoetis USD 1.03B 88M Sep/2026